Hapvida (OTC: HAPVY)

$10.01+0.00%today

Brazilian ADR trading on the OTC, priced in US dollars.

Display currency

Market Cap, EPS and the financial totals below — switch between US dollars and BRL.

Market Cap: $613.32M
P/E (TTM): —
P/B: 0.5x
EPS (TTM): $-0.17
Dividend Yield: —
52-Week Range: $1.81 – $10.01
Volume: 200
Previous Close: $10.01

TTM = trailing twelve months — the most recent 12 months (a rolling window), used for P/E, EPS and dividends. On the tables and charts below, the in-progress current year appears as a “Last 12M” column labelled with the quarter range it covers.

Performance

Today

+0.00%

1 Week

+0.00%

1 Month

+0.00%

YTD

+0.00%

1 Year

+0.00%

5 Years

—

About Hapvida

US Ticker: HAPVY
B3 Ticker: HAPV3
Exchange: OTC
Currency: USD
Sector: Financial Services
Industry: Insurance - Life
Headquarters: Fortaleza, CE, Brazil
Employees: —
CEO: Mr. Luccas Augusto Adib
Founded: 1979

Hapvida Participações e Investimentos S.A., together with its subsidiaries, operates in the healthcare sector in Brazil.

It sells health insurance plans through its own clinical, outpatient, and hospital networks, as well as dental plans through an accredited network.

Hapvida Participações e Investimentos S.A. was founded in 1979 and is headquartered in Fortaleza, Brazil.

ri.hapvida.com.br

Financial Results

Revenue, EBITDA and net profit (in USD) with net margin (net profit ÷ revenue).

Financial Health

Margins, leverage and cash-flow quality derived from Hapvida's income statement, balance sheet and cash flow (absolute figures in USD).

ProfitabilityLeverageGrowth

Overall: Financially Stretched

Net Margin: -1.3%
ROE: -0.9%
Rev Growth (YoY): +0.86%
Net Debt / EBITDA: 3.88×
Current Ratio: 1.79×
Interest Coverage: 0.83×
Free Cash Flow: —
Payout Ratio: —

Income — Margins & Efficiency

Metric	Last 12MQ2'25 – Q1'26	Δ	2025	Δ	2024	Δ	2023	Δ	2022
Revenue	$6,133,284,740	+6.4%	$5,766,268,580	+23.2%	$4,680,344,130	-18.8%	$5,762,560,925	+28.2%	$4,493,964,160
Gross profit	$706,818,479	+4.0%	$679,949,417	+27.3%	$534,283,980	-18.6%	$656,060,575	-38.7%	$1,070,108,617
Operating income	$366,655,369	+5.2%	$348,419,890	+24.2%	$280,566,374	-19.4%	$347,897,612	+3643.6%	$9,293,040
EBITDA	$744,720,960	+0.8%	$739,012,089	+38.0%	$535,608,378	-22.9%	$695,045,153	+56.5%	$443,997,654
Net profit	-$82,584,540	-219.1%	-$25,884,190	+75.4%	-$105,100,601	+17.1%	-$126,830,028	+13.8%	-$147,075,275
Gross margin	11.5%	-0.3 p.p.	11.8%	+0.4 p.p.	11.4%	+0.0 p.p.	11.4%	-12.4 p.p.	23.8%
Operating margin	6.0%	-0.1 p.p.	6.0%	+0.0 p.p.	6.0%	-0.0 p.p.	6.0%	+5.8 p.p.	0.2%
EBITDA margin	12.1%	-0.7 p.p.	12.8%	+1.4 p.p.	11.4%	-0.6 p.p.	12.1%	+2.2 p.p.	9.9%
Net margin	-1.3%	-0.9 p.p.	-0.4%	+1.8 p.p.	-2.2%	-0.0 p.p.	-2.2%	+1.1 p.p.	-3.3%
Revenue growth (YoY)	0.9%	-8.3 p.p.	9.2%	+5.8 p.p.	3.5%	-14.2 p.p.	17.7%	—	—
Effective tax rate	10.3%	-28.9 p.p.	39.2%	+79.4 p.p.	-40.2%	-27.2 p.p.	-13.1%	-59.5 p.p.	46.4%
Interest coverage	0.83×	-8.7%	0.91×	+18.2%	0.77×	+1.4%	0.76×	+670.2%	0.10×

Newest column (“Last 12M”) = trailing 12 months, the last 4 reported quarters — shown with the quarter range it spans; earlier columns are full fiscal years.

Balance Sheet — Health & Leverage

Metric	Last 12MQ2'25 – Q1'26	Δ	2025	Δ	2024	Δ	2023	Δ	2022
Net debt	$2,892,982,014	+8.7%	$2,662,187,283	+3.3%	$2,577,401,706	-6.9%	$2,769,840,213	+14.4%	$2,422,096,280
Net Debt / Equity	0.31×	+3.3%	0.30×	-7.6%	0.33×	+21.0%	0.27×	+4.1%	0.26×
Net Debt / EBITDA	3.88×	+7.8%	3.60×	-25.1%	4.81×	+20.8%	3.99×	-26.9%	5.46×
Debt / Equity	0.33×	+3.4%	0.32×	-5.6%	0.34×	+13.4%	0.30×	+4.8%	0.29×
Current ratio	1.79×	-5.7%	1.90×	-9.9%	2.11×	+44.1%	1.46×	+23.5%	1.18×
Return on equity (ROE)	-0.9%	-0.6 p.p.	-0.3%	+1.0 p.p.	-1.3%	-0.1 p.p.	-1.2%	+0.3 p.p.	-1.6%
Return on assets (ROA)	-0.6%	-0.4 p.p.	-0.2%	+0.7 p.p.	-0.9%	-0.0 p.p.	-0.8%	+0.2 p.p.	-1.1%
Book value / share	$19.52	+5.2%	$18.56	+16.5%	$15.93	-22.3%	$20.50	+4.1%	$19.69

Newest column (“Last 12M”) = trailing 12 months, the last 4 reported quarters — shown with the quarter range it spans; earlier columns are full fiscal years.

Net Debt & Leverage

Free Cash Flow

Margins

Dividend Payout Ratio

Capex ÷ Revenue

Cash Conversion (operating cash flow ÷ net income)

Ratios computed from company financial statements. Net Debt = total debt − cash & equivalents; FCF = operating cash flow − capital expenditure; absolute values in USD.

Valuation & Dividends

Dividend History

$0.00

Hapvida has not paid dividends over the past decade.

Dividends and yield from Yahoo Finance (per ADR share, in US dollars). The current-year figures are calendar year-to-date (dividends actually paid this year), not the trailing 12 months.

Listings

Hapvida trades on 2 exchanges. Prices on this page are the OTC ADR (HAPVY).

Exchange	Ticker	Currency
OTCpriced here	HAPVY	USD
B3 (São Paulo)	HAPV3	BRL

Frequently Asked Questions

Why hold Hapvida HAPVY ADR instead of local B3 HAPV3 shares?

Buying directly on Brazil’s B3 exchange means opening a local brokerage account, converting currency and dealing with Brazilian tax paperwork. ADRs remove that friction: they settle in dollars, follow US market hours, and report in formats foreign investors already understand.

The trade-off is that an ADR’s price reflects two moving parts: (1) the underlying share price, quoted in reais on the B3, and (2) the USD/BRL exchange rate. Because of that second part, a rising company can still deliver a flat, or even negative, dollar return if the real weakens against the dollar. The same applies to ETFs: funds such as EWZ, EWZS and FLBR bundle dozens of these companies into a single ticker for instant diversification, but their dollar value still moves with the real.

Where is Hapvida listed?

Hapvida trades on 2 exchanges. The line quoted on this page is OTC in the United States (HAPVY, US dollars). It also trades on B3 (São Paulo) in Brazil (HAPV3, Brazilian reais).

On how many exchanges does Hapvida trade?

2. OTC — HAPVY (USD) · B3 (São Paulo) — HAPV3 (BRL). Prices shown on this page are the OTC line, HAPVY.

What is Hapvida's primary listing?

Hapvida's primary listing is on the B3 in Brazil, where the shares trade as HAPV3 in reais — the company's home market. The OTC line quoted on this page is an ADR over those same shares: it gives you the asset in US dollars, on US market hours, without opening a Brazilian brokerage account or trading in reais.

What is the difference between HAPVY and HAPV3?

They are the same company and, economically, the same asset. HAPV3 is the original Brazilian share, listed on the B3 and quoted in reais. HAPVY is an American Depositary Receipt over that share, listed on the OTC and quoted in US dollars — a wrapper whose purpose is to give foreign investors access to the Brazilian asset without opening an account in Brazil. The HAPVY price therefore tracks two things: HAPV3 in reais, and the USD/BRL exchange rate.

How can I buy Hapvida stock in the United States?

Hapvida is listed on the OTC under HAPVY, priced in US dollars. Any US brokerage offering over-the-counter securities can trade it, with no foreign-account paperwork and no currency conversion.

As of Fri, Aug 14, 17:00 BRT · Market closed

Financial data last updated: July 22, 2026

← All stocks & ETFs